ipamorelin safety adverse effects clinical trial events An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results Ipamorelin FDA Approval Status 2026:

10.1111/j.1749-6632.2002.tb02938.x Ann

Chem Res Toxicol 22:18331840

an effect transmissible via FMT ( P.g also induces metabolic syndrome (MetS) and insulin resistance by disrupting gut microbiota, impairing the gut barrier, and inactivating AHR signaling ( P.g exacerbates both alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD/MASLD) via the gut-liver axis, promoting inflammation, fibrosis, and even hepatocyte ferroptosis through mechanisms involving the LPS-TLR4 pathway and disrupted bile acid metabolism ( P.g causes periodontal microbiota dysbiosis and systemic insulin resistance without major gut microbiota alterations ( The neurological and neuropsychiatric systems are profoundly affected via the gut-brain axis

Gareau et al., 2011